The FDA has given its authorization to a Novavax COVID-19 vaccine designed for the autumn vaccination phase, adding a new contender to the messenger RNA vaccines already being disseminated across the nation. However, this FDA decision, announced on Tuesday, is not an approval but rather an update to last year’s emergency authorization that now includes a revised formula to deal with current variants.
In comparison to the original Novavax vaccine, which was authorized for individuals aged 18 and older, this refreshed version has expanded its reach to include those aged 12 and up. Novavax’s initial vaccine, directed at the original SARS-CoV-2 strain, is now ineligible for use in the United States due to this regulatory update.
The updated vaccine is built using Novavax’s proprietary protein-based vaccine technology. It is tweaked for improved recognition and responsiveness to XBB.1.5, an Omicron variant identical to the target of the updated messenger RNA vaccines.
Since June, newer strains have emerged and vaccines, including Novavax’s and those based on the mRNA technology, have responded. Both have shown healthy, robust antibody responses in the face of recent variants now prevalent in the USA and Europe. These outcomes are based on non-clinical data showing defense responses against XBB.1.5, XBB.1.16, and XBB.2.3.
This has serious ramifications for legal professionals in an advisory capacity to pharmaceutical corporations or law firms that deal with medical legislation or disputes. Novavax’s vaccine carries an adjuvant, which amplifies its immune response, meaning a reduced dosage can achieve the intended effect – an aspect that expands Novavax’s potential for vaccine manufacture.
The FDA has authorized Novavax’s updated vaccine for those previously vaccinated with any Covid-19 shot as a single shot, and also for those unvaccinated who must take two shots, three weeks apart. Additional details about vaccine timing and dosing can be found here.
Novavax’s CEO, John Jacobs, has appreciated this authorization, signifying users now have the option of a protein-based, non-MRNA vaccine to protect against Covid-19. Appointments can now be scheduled at pharmacies, clinics, and other such venues for the updated Novavax vaccine.